New York, October 15, 2026 / PRNewswire / -- Global leading healthcare investment firm OrbiMed announced that it has raised $3 billion in committed funds for two new private equity funds, namely OrbiMed Private Investments X and OrbiMed Asia Partners VI.
OrbiMed indicates that OrbiMed Private Investments X has raised over $1.9 billion and will invest in venture capital opportunities in the life sciences sector in the United States and Europe. OrbiMed Asia Partners VI has raised over $1 billion and will invest in venture capital and growth opportunities in the healthcare sector in Asia. The goal of both funds is to build leading healthcare companies, with a focus on biopharmaceuticals, medical devices, diagnostics, and technology-driven medical services.
"There has never been a better time to invest in life science innovation," said Carl Gordon, managing partner of OrbiMed. "The continuous advancement of artificial intelligence and new treatment modalities, along with China's rise as a powerhouse in biotechnology, are exponentially expanding the opportunities for developing transformative therapies. We look forward to helping entrepreneurs turn these advancements into leading enterprises in the healthcare industry."
OrbiMed indicates that the company is led by 20 partners and has a team of over 150 professionals who possess complementary expertise in business incubation, strategy, operations, and finance. The company operates in 12 locations around the world, covering major healthcare markets.
Investors in these new funds include a wide range of institutional types, such as medical institutions, university endowment funds, foundations, pension funds, sovereign wealth funds, and family offices.
"We are grateful for the continuous support of our many long-term investors," said Carter Neild, managing partner of OrbiMed. "In the coming years, we will make unremitting efforts to meet their high expectations."
About OrbiMed
OrbiMed is a leading healthcare investment company that manages assets worth over $21 billion. OrbiMed indicates that the company invests across the entire healthcare industry globally, covering everything from startups to large multinational corporations. Its investment tools include private equity funds, listed equity funds, as well as royalty/credit funds. OrbiMed aims to become the preferred capital provider, helping to build world-class healthcare enterprises by offering customized financing solutions and leveraging its strong global team resources.
The OrbiMed team is composed of over 150 professionals, distributed across New York, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other major global markets. For more information, please visit www.orbimed.com.
